Hunter's Canal Syndrome, Hunter's Syndrome, Mild Form, Hunter Syndrome, Mucopolysaccharidosis II
Conditions
Keywords
Hunter Disease, Biomarker
Brief summary
International, multicenter, observational, longitudinal study to establish Hunter Syndrom biomarker/s and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s
Detailed description
Mucopolysaccharides are long chains of sugar carbohydrates, found within the cells that help build bone, cartilage, tendons, cornea, skin, and connective tissue. Glycosaminoglycans (GAGs) are also found in the fluids that lubricate joints. Mucopolysaccharidosis (MPS) are part of the Lysosomal Storage Disorder (LSD) family, a group of more than 40 genetic diseases, and occur when a particular enzyme exists in a small quantity or is missing altogether. The effect is the accumulation of GAGs in the cells, blood, and connective tissues, resulting in permanent and progressive cellular damage which affects appearance, physical abilities, organ and system functioning and, in most cases, mental development. MPS2 (also called Hunter syndrome) is a hereditary, progressive, multisystemic disorder, caused by mutations in the IDS gene coding for the enzyme iduronate sulfatase (Ids). It is the only type of mucopolysaccharidosis that is X-linked, therefore, if mothers are carriers, there is a 50 percent chance for males to be born with the disease. MPS2 has a wide range of symptoms that vary in severity, which can be managed with enzyme replacement therapy (ERT). ERT is unable to cross the blood-brain barrier, therefore it addresses strictly extra-neurological manifestations. On this note, further efforts are being made to develop novel therapies, in the attempt to stop the disease progression and to offer a better quality of life to the patients. As MPS2 is very rare and many medical professionals only see a few or no patients in their lifelong practice, genetic testing is crucial for diagnosis. This study thrives to identify, validate, and monitor potential biomarker/s for MPS2 in genetically confirmed samples.
Interventions
None listed
Sponsors
CENTOGENE GmbH Rostock
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
2 Months to 50 Years
Healthy volunteers
No
Inclusion criteria
* Male individuals * Informed consent is obtained from the participant's parent/legal guardian * The participant is aged between 2 months and 50 years of age * The diagnosis of MPS II is genetically confirmed by CENTOGENE
Exclusion criteria
* Females * Informed consent is not provided by the participant's parent/legal guardian * The participant is younger than 2 months or older than 50 years of age * The diagnosis of MPS II is not genetically confirmed by CENTOGENE
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identifying MPS II biomarkers | 36 weeks | All samples will be analyzed for the identification of biomarker/s via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To explore the clinical robustness, specificity, and long-term variability of MPS II biomarkers | 36 months | Samples will be analyzed for the identified biomarker candidates via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC. |
Countries
Mexico
Outcome results
None listed